ChatGPT

Perplexity

Gemini

Claude

Grok

Title: DIMS

Short description: 
DIMS is the Best offline mobile drug index of Bangladesh.

Full description:

Key Features & Benefits

1. Drugs details (Indications, Dosage & administrations, Contrai

Introducing HalfLife for IOS: a precision tracking tool designed to help users understand compound half-lives and pharmacokinetics through a simple, structured interface.
Whether you're managing compl

The Medical Letter publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common conditions in its biweekly newsletter The Medical Letter on Drugs and Therapeutic

Superluminal

“Biopharma returns to MC4R for drugs targeting genetic obesity as well as appetite loss.” Featured Story on Endpoints News by Kyle LaHucik

Superluminal combines cutting-edge AI with deep expertise in structural biology and protein dynamics to solve problems that have stymied traditional approaches.

Scientific Excellence

The company's name reflects its commitment to moving faster than light in drug discovery, compressing timelines through AI-enabled approaches.

Speed

By targeting GPCRs in obesity and cardiometabolic disease, Superluminal addresses conditions affecting hundreds of millions of patients globally.

Impact

Strategic partnerships with industry leaders like Eli Lilly and NVIDIA combine Superluminal's platform with world-class drug development and computing capabilities.

Collaboration

Superluminal Medicines uses AI and structural biology to rapidly discover GPCR-targeted drugs, securing a $1.3 billion Eli Lilly partnership for obesity drugs and advancing its lead MC4R program toward human trials.

Cony D'Cruz

Co-Founder & CEO

Ajay Yekkirala

Co-Founder & SVP, Head of Discovery

Yang-Ming Zhu

SVP, Head of Engineering

Yamina A. Berchiche

Senior Director, Biology

Marek Orzechowski

Director, Computational Chemistry

Murco Ringnalda

SVP, Head of Operations

Proprietary AI platform integrating machine learning, protein dynamics, and structural biology to rapidly discover drugs targeting GPCRs that have resisted traditional approaches.

GPCR Drug Discovery Platform

Lead internal program developing selective, biased melanocortin 4 receptor agonist for treatment of rare genetic obesity, hypothalamic obesity, and potentially general obesity in combination with GLP-1 drugs.

MC4R Obesity Program

Multi-target collaboration with Eli Lilly to discover small molecule therapeutics for undisclosed GPCR targets relevant to cardiometabolic diseases and obesity.

Eli Lilly Collaboration Programs

Eli Lilly entered a $1.3 billion agreement with Superluminal to leverage AI in developing small-molecule drugs targeting GPCRs for obesity and cardiometabolic diseases.

Eli Lilly Strikes $1.3 Billion AI Drug Discovery Deal with Superluminal Medicines

Superluminal announced its selective, biased MC4R agonist is advancing to IND-enabling studies for obesity treatment, with human trials expected by Q4 2026.

Superluminal Announces MC4R Agonist Advancing to IND-enabling Studies

Superluminal closed $120 million Series A led by RA Capital Management with participation from Insight Partners, NVIDIA NVentures, and Eli Lilly to advance GPCR drug discovery.

Superluminal Medicines Closes $120 Million Series A Round

Industry analysis highlighting Superluminal's Eli Lilly deal as one of the most significant AI biotech partnerships of 2025.

The 2025 AI biotech deals every executive should watch

With all of the recent talk surrounding AI deals, I thought I’d look into each of Nvidia’s recent deals and what impact they have. Did I miss anything significant? Thoughts?

[HIRING] a CryoEM Laboratory Technician at Superluminal Medicines! in Superluminal Medicines

NvidiaStock

jobboardsearch

MEDI Group Ltd

Cony D'Cruz and Ajay Yekkirala founded Superluminal Medicines in Boston to apply AI and structural biology to GPCR drug discovery.

Company Founded

Launched with $33 million seed round to fuel drug discovery engine and build initial pipeline of small molecule therapeutics targeting GPCRs.

Seed Funding

Advanced AI platform integrating machine learning with protein dynamics and structural biology for GPCR drug discovery.

Platform Development

Closed $120 million Series A led by RA Capital Management with participation from Insight Partners, NVIDIA NVentures, Eli Lilly, and others.

Series A Funding

Announced selective, biased MC4R agonist advancing to IND-enabling studies for obesity treatment, targeting human trials by Q4 2026.

MC4R Program Advances to IND

Secured $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases targeting GPCR targets.

Eli Lilly Partnership

For use with the engineering kits “Robotics: Smart Machines”, “Robotics: Smart Machines - Rovers & Vehicles Edition”, and “Robotics: Smart Machines - Tracks & Treads Edition” by Thames & Kosmos.

This

The Blue Alliance is a tool to help FIRST Robotics teams scout for, compete at, and relive competitions.

The Blue Alliance app is the easiest way to access all the great content on thebluealliance.co

1. Smart connection, multi-device management. 
2. Share with your family, a more relaxed lifestyle. 
3. Support OTA remote upgrade. 
4. Duration The working time of the Robotic Pool Cleaner can be set

Bucket Robotics is an AI defect detection platform from YC batch making defect detection faster more deployable starting with 250M lbs plastic wasted annually in US manufacturing turning CAD files into defect detectors using AI vision for quality control enabling manufacturers reduce waste improve quality targeting manufacturers through AI defect detection YC batch.

Superluminal Medicines vs Bucket Robotics

Superluminal Medicines

About

Bucket Robotics

About

AI Visibility Head-to-Head

Also Compare

Track AI Visibility in Real Time